10
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      CD163+ immune cell infiltrates and presence of CD54+ microvessels are prognostic markers for patients with embryonal rhabdomyosarcoma

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Rhabdomyosarcomas (RMS) are rare and often lethal diseases. It is assumed that the tumor microenvironment (TME) of RMS exerts an immunosuppressive function, but there is currently no systematic analysis of the immune cells infiltrating sarcoma tissue. Focusing on two common types of RMS (alveolar [RMA] and embryonal [RME]), we performed a comprehensive immunohistochemical analysis of tumor-infiltrating immune cells in the TME. We performed a qualitative estimation of infiltrating immune cells in the tumor microenvironment by an experienced pathologist as well as a quantitative digital pathology analysis. We found that (1) manual and automatic quantification of tumor-infiltrating immune cells were consistent; (2) RME tumors showed a higher degree of immune cell infiltration than RMA tumors but (3) the number of tumor infiltrating lymphocytes was low compared to other solid tumor types; (4) microvascular density correlated with immune cell infiltration and (5) CD163 positive macrophages as well as CD54 positive microvessels were more often detected in RME than in RMA and correlated with patient overall and event free survival. Our systematic analysis provides a comprehensive view of the immune landscape of RMS which needs to be taken into account for developing immunotherapies for this rare type of cancer.

          Related collections

          Most cited references40

          • Record: found
          • Abstract: found
          • Article: not found

          The blockade of immune checkpoints in cancer immunotherapy.

          Among the most promising approaches to activating therapeutic antitumour immunity is the blockade of immune checkpoints. Immune checkpoints refer to a plethora of inhibitory pathways hardwired into the immune system that are crucial for maintaining self-tolerance and modulating the duration and amplitude of physiological immune responses in peripheral tissues in order to minimize collateral tissue damage. It is now clear that tumours co-opt certain immune-checkpoint pathways as a major mechanism of immune resistance, particularly against T cells that are specific for tumour antigens. Because many of the immune checkpoints are initiated by ligand-receptor interactions, they can be readily blocked by antibodies or modulated by recombinant forms of ligands or receptors. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) antibodies were the first of this class of immunotherapeutics to achieve US Food and Drug Administration (FDA) approval. Preliminary clinical findings with blockers of additional immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumour immunity with the potential to produce durable clinical responses.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The Integrated Genomic Landscape of Thymic Epithelial Tumors

            Thymic epithelial tumors (TETs) are one of the rarest adult malignancies. Among TETs, thymoma is the most predominant, characterized by a unique association with autoimmune diseases, followed by thymic carcinoma which is less common but more clinically aggressive. Using multi-platform omics analyses on 117 TETs, we define four subtypes of these tumors defined by genomic hallmarks and an association with survival and WHO histological subtype. We further demonstrate a marked prevalence of a thymoma-specific mutated oncogene GTF2I, and explore its biological effects on multi-platform analysis. We further observe enrichment of mutations in HRAS, NRAS, and TP53. Lastly, we identify a molecular link between thymoma and the auto-immune disease myasthenia gravis, characterized by tumoral over-expression of muscle auto-antigens, and increased aneuploidy. Radovich et al. perform multi-platform analyses of thymic epithelial tumors. They identify high prevalence of GTF2I mutations and enrichment of mutations in HRAS , NRAS , and TP53 and link over-expression of muscle auto-antigens and increased aneuploidy in thymoma and patients’ risk of having myasthenia gravis.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Tumor mutational burden is a determinant of immune-mediated survival in breast cancer

              ABSTRACT Mounting evidence supports a role for the immune system in breast cancer outcomes. The ability to distinguish highly immunogenic tumors susceptible to anti-tumor immunity from weakly immunogenic or inherently immune-resistant tumors would guide development of therapeutic strategies in breast cancer. Genomic, transcriptomic and clinical data from The Cancer Genome Atlas (TCGA) and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) breast cancer cohorts were used to examine statistical associations between tumor mutational burden (TMB) and the survival of patients whose tumors were assigned to previously-described prognostic immune subclasses reflecting favorable, weak or poor immune-infiltrate dispositions (FID, WID or PID, respectively). Tumor immune subclasses were associated with survival in patients with high TMB (TMB-Hi, P < 0.001) but not in those with low TMB (TMB-Lo, P = 0.44). This statistical relationship was confirmed in the METABRIC cohort (TMB-Hi, P = 0.047; TMB-Lo, P = 0.39), and also found to hold true in the more-indolent Luminal A tumor subtype (TMB-Hi, P = 0.011; TMB-Lo, P = 0.91). In TMB-Hi tumors, the FID subclass was associated with prolonged survival independent of tumor stage, molecular subtype, age and treatment. Copy number analysis revealed the reproducible, preferential amplification of chromosome 1q immune-regulatory genes in the PID immune subclass. These findings demonstrate a previously unappreciated role for TMB as a determinant of immune-mediated survival of breast cancer patients and identify candidate immune-regulatory mechanisms associated with immunologically cold tumors. Immune subtyping of breast cancers may offer opportunities for therapeutic stratification.
                Bookmark

                Author and article information

                Contributors
                katja.simon-keller@medma.uni-heidelberg.de
                Journal
                Sci Rep
                Sci Rep
                Scientific Reports
                Nature Publishing Group UK (London )
                2045-2322
                25 June 2019
                25 June 2019
                2019
                : 9
                : 9211
                Affiliations
                [1 ]ISNI 0000 0004 0492 0584, GRID grid.7497.d, Applied Tumor Immunity, , German Cancer Research Center, ; Heidelberg, Germany
                [2 ]ISNI 0000 0000 8653 1507, GRID grid.412301.5, Internal Medicine III, , University Hospital RWTH Aachen, ; Aachen, Germany
                [3 ]ISNI 0000 0001 2162 1728, GRID grid.411778.c, Institute of Pathology, , University Medical Center Mannheim, ; Mannheim, Germany
                [4 ]ISNI 0000 0001 2190 5763, GRID grid.7727.5, Center of Plastic-, Hand- and Reconstructive Surgery, , University of Regensburg, ; Regensburg, Germany
                [5 ]Institute of Pathology, Paidopathology, University Medical Center Kiel, Kiel, Germany
                [6 ]ISNI 0000 0001 2162 1728, GRID grid.411778.c, Department of Medical Statistics and Biomathematics, , University Medical Centre Mannheim, ; Mannheim, Germany
                [7 ]ISNI 0000 0004 0493 3975, GRID grid.459687.1, Pediatrics 5 (Oncology, Hematology, Immunology), , Olgahospital, Klinikum Stuttgart, ; Stuttgart, Germany
                Author information
                http://orcid.org/0000-0001-9722-2483
                http://orcid.org/0000-0003-2340-8765
                Article
                45551
                10.1038/s41598-019-45551-y
                6592899
                31239476
                47007c8e-e353-4371-abbd-c4d12feb52ee
                © The Author(s) 2019

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 8 March 2019
                : 7 June 2019
                Funding
                Funded by: The Margarete von Wrangell Fellowship is a support programme for young female scientists in Baden-W&amp;#x00FC;rttemberg [gant number 31-7635.41/35/2]. The SEED Foundation funds were provided by the Medical Faculty Mannheim.
                Categories
                Article
                Custom metadata
                © The Author(s) 2019

                Uncategorized
                predictive markers,cancer microenvironment
                Uncategorized
                predictive markers, cancer microenvironment

                Comments

                Comment on this article